X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs BIOCON LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA BIOCON LTD SANOFI INDIA/
BIOCON LTD
 
P/E (TTM) x 30.3 36.6 82.9% View Chart
P/BV x 5.4 4.9 110.1% View Chart
Dividend Yield % 1.7 1.5 110.8%  

Financials

 SANOFI INDIA   BIOCON LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
BIOCON LTD
Mar-16
SANOFI INDIA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs4,560496 919.9%   
Low Rs4,400397 1,109.7%   
Sales per share (Unadj.) Rs1,028.5174.3 590.2%  
Earnings per share (Unadj.) Rs129.044.8 287.8%  
Cash flow per share (Unadj.) Rs186.056.9 326.7%  
Dividends per share (Unadj.) Rs68.005.00 1,360.0%  
Dividend yield (eoy) %1.51.1 135.4%  
Book value per share (Unadj.) Rs753.6202.8 371.6%  
Shares outstanding (eoy) m23.03200.00 11.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.6 170.2%   
Avg P/E ratio x34.710.0 348.9%  
P/CF ratio (eoy) x24.17.8 307.4%  
Price / Book Value ratio x5.92.2 270.2%  
Dividend payout %52.711.2 472.5%   
Avg Mkt Cap Rs m103,17489,220 115.6%   
No. of employees `0003.64.4 82.1%   
Total wages/salary Rs m3,5926,363 56.5%   
Avg. sales/employee Rs Th6,537.77,894.5 82.8%   
Avg. wages/employee Rs Th991.41,441.2 68.8%   
Avg. net profit/employee Rs Th819.82,029.7 40.4%   
INCOME DATA
Net Sales Rs m23,68634,854 68.0%  
Other income Rs m708845 83.8%   
Total revenues Rs m24,39435,699 68.3%   
Gross profit Rs m5,2818,200 64.4%  
Depreciation Rs m1,3132,423 54.2%   
Interest Rs m15102 14.7%   
Profit before tax Rs m4,6616,520 71.5%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m1,6912,569 65.8%   
Profit after tax Rs m2,9708,961 33.1%  
Gross profit margin %22.323.5 94.8%  
Effective tax rate %36.339.4 92.1%   
Net profit margin %12.525.7 48.8%  
BALANCE SHEET DATA
Current assets Rs m15,67339,932 39.2%   
Current liabilities Rs m6,67816,276 41.0%   
Net working cap to sales %38.067.9 56.0%  
Current ratio x2.32.5 95.7%  
Inventory Days Days7654 141.9%  
Debtors Days Days2286 25.9%  
Net fixed assets Rs m8,09839,101 20.7%   
Share capital Rs m2301,000 23.0%   
"Free" reserves Rs m17,08838,591 44.3%   
Net worth Rs m17,35640,556 42.8%   
Long term debt Rs m020,724 0.0%   
Total assets Rs m25,40084,816 29.9%  
Interest coverage x311.764.9 480.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.4 226.9%   
Return on assets %11.810.7 110.0%  
Return on equity %17.122.1 77.4%  
Return on capital %26.919.0 141.9%  
Exports to sales %24.530.7 79.7%   
Imports to sales %28.020.4 137.3%   
Exports (fob) Rs m5,80110,717 54.1%   
Imports (cif) Rs m6,6277,105 93.3%   
Fx inflow Rs m7,14511,789 60.6%   
Fx outflow Rs m6,8468,393 81.6%   
Net fx Rs m2993,396 8.8%   
CASH FLOW
From Operations Rs m3,2265,264 61.3%  
From Investments Rs m-1,555-9,540 16.3%  
From Financial Activity Rs m-1,81810,867 -16.7%  
Net Cashflow Rs m-1476,591 -2.2%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 60.4 20.6 293.2%  
Indian inst/Mut Fund % 14.4 8.4 171.4%  
FIIs % 14.6 10.7 136.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   15,184 109,995 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS